Case report on diclofenac induced stevens-johnson syndrome

Venkata Nagaraju G; Mariyabi SK

doi:10.70604/jmtbas.v1i2.27

Authors

G Venkata Nagaraju Department of Pharmacy Practice, Hindu College of Pharmacy, Guntur.
SK. Mariyabi Department of Pharmacy Practice, Hindu College of Pharmacy, Guntur.

Abstract

Stevens-Johnson Syndrome (SJS) is a rare, severe hypersensitivity disorder affecting the skin and mucous membranes. It is primarily triggered by adverse reactions to medications or infections and is considered a medical emergency. The syndrome initially presents with flu-like symptoms, including fever and fatigue, followed by a painful, widespread rash, blistering, and detachment of the skin and mucosal surfaces. Common causative agents include antibiotics, anti-seizure drugs, NSAIDs, and infections such as Mycoplasma pneumoniae or herpes simplex. Diagnosis relies on clinical evaluation and skin biopsy when needed.

Keywords:

Stevens-Johnson syndrome, Skin and mucous membrane disorder, Drug reaction

DOI

https://doi.org/10.70604/jmtbas.v1i2.27

References

1. Jha N, Alexander E, Kanish B, Badyal DK. A Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Center in Punjab. Indian Dermatol online J. 2018 Sep-Oct;9(5):299-303 [PMC free article] [PubMed]

2. Auyeng J, Lee M. Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid. Can J Hosp Pharm. 2018 Jul-Aug; 71(4):272-275 [PMC free article] [PubMed]

3. Iyer G, Srinivasan B, Agrawal S, Ravindran R, Rishi E, Rishi P, Krishnamoorthy s. Boston Type 2 Keratoprosthesis-mid term outcomes from a tertiary eye care Centre in India. Ocul Surf. 2019 Jan; 17(1):50-54 [PubMed]

4. Chung, W. H., et al. (2004). Medical genetics: A marker for Stevens-Johnson syndrome. Nature, 428(6982), 486.

5. Mockenhaupt, M., et al. (2008). The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with NSAIDs. Epidemiology, 19(2), 303-309.

6. Bellón, T., et al. (2009). Immunopathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. Current Opinion in Allergy and Clinical Immunology, 9(4), 294-300.

7. Shi, Y. W., et al. (2012). HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: A meta-analysis. Epilepsia, 53(3), 517-525.

8. Hung, S. I., et al. (2005). Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics, 15(4), 297-306.

9. Bastuji-Garin, S., et al. (1993). Toxic epidermal necrolysis (Lyell syndrome): Incidence and drug etiology in France, 1981–1985. Archives of Dermatology, 129(1), 37-42.

10. Pichler, W. J. (2003). Delayed drug hypersensitivity reactions. Annals of Internal Medicine, 139(8), 683-693.

11. White, K. D., et al. (2015). Understanding the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy, 70(9), 938-949.

12. Choudhary, S., et al. (2016). Clinical manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis: A review. Indian Journal of Dermatology, 61(3), 290-295.

13. Cacoub, P., et al. (2000). Severe cutaneous adverse reactions: Clinical features, management, and prognosis. International Journal of Dermatology, 39(8), 543-548.

14. Fagot, J. P., et al. (2001). Incidence and risk factors for Stevens-Johnson syndrome and toxic epidermal necrolysis in the French population. Pharmacological Research, 43(5), 237-243.

15. John, A., & Diamond, G. (2011). The clinical spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: An update. Journal of Clinical Medicine, 5(2), 142-148

16. Roujeau, J. C., & Stern, R. S. (1994). Severe adverse cutaneous reactions to drugs. New England Journal of Medicine, 331(19), 1272-1285.

17. Fritsch, P. O., & Sidoroff, A. (2000). Severe drug-induced skin reactions. Allergy, 55(12), 1216-1225.

18. High, W. A., et al. (2006). Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical presentations, and treatment. Journal of the American Academy of Dermatology.

19. Wang, C. W., et al. (2013). Immunopathogenesis and risk factors for allopurinol severe cutaneous adverse reactions. Current Opinion in Allergy and Clinical Immunology.

20. Kim, K. J., et al. (2016). Management of Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Clinical Dermatology.